Cholesterol 750mg/5ml oral suspension
Prescription only
Requires a prescription from a doctor or prescriber
Oral suspension
750mg/5ml
Oral
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Active ingredients:
Cholesterol
No active safety alerts
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Show details
Therapeutically similar medicines
Show details
Acoramidis 356mg tablets
Tablet
356mg
Same BNF section
Sodium phenylbutyrate 350mg/ml oral solution sugar free
Oral solution
350mg
Same BNF section
Pegunigalsidase alfa 5mg/2.5ml solution for infusion vials
Infusion
5mg/2.5ml
Same BNF section
Pegzilarginase 2mg/0.4ml solution for injection vials
Injection
2mg/0.4ml
Same BNF section
Vestronidase alfa 10mg/5ml solution for infusion vials
Infusion
10mg/5ml
Same BNF section
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Show details
Loading prescribing data...
Clinical guidelines and formulary information
British National Formulary
Cholesterol
BNF
Drug monograph — bnf.nice.org.ukSource: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(7)
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
NG238
NICE guideline
Updated Dec 2023Cardiovascular risk assessment and lipid modification (QS100)
QS100
Quality standard
Updated Jul 2025Familial hypercholesterolaemia: identification and management (CG71)
CG71
Clinical guideline
Updated Oct 2019Familial hypercholesterolaemia (QS41)
QS41
Quality standard
Updated Nov 2017Chronic kidney disease in adults (QS5)
QS5
Quality standard
Updated Jul 2017Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
TA385
Technology appraisal
Updated Feb 2016Type 1 diabetes in adults (QS208)
QS208
Quality standard
Updated Mar 2023Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Show details
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
Show details
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).
Active and completed clinical studies from ClinicalTrials.gov
Show details
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
5 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Status:
Approved
Investigational
Withdrawn
Small molecule
About this compound
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Properties:
solid
Avg. mass: 386.65 Da
Also known as(47)
(3β,14β,17α)-cholest-5-en-3-ol
Cholest-5-en-3beta-ol
Cholesterin
Cholesterol
2.7.7.15
CCT B
CCT-beta
CCTB
Molecular properties(19)
Drug interactions(100)
Known interactions with other medications. Always consult a healthcare professional.
Folic acid
Moderate
Cholesterol may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.
Allopurinol
Moderate
Cholesterol may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.
Oxaliplatin
Moderate
Cholesterol may increase the excretion rate of Oxaliplatin which could result in a lower serum level and potentially a reduction in efficacy.
Fluorouracil
Moderate
Cholesterol may increase the excretion rate of Fluorouracil which could result in a lower serum level and potentially a reduction in efficacy.
Testosterone
Moderate
Cholesterol may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.
Clofarabine
Moderate
Cholesterol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Riluzole which could result in a lower serum level and potentially a reduction in efficacy.
Sulfasalazine
Moderate
Cholesterol may increase the excretion rate of Sulfasalazine which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Glyburide which could result in a lower serum level and potentially a reduction in efficacy.
Leflunomide
Moderate
Cholesterol may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy.
Rosuvastatin
Moderate
Cholesterol may increase the excretion rate of Rosuvastatin which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Alvocidib which could result in a lower serum level and potentially a reduction in efficacy.
Teriflunomide
Moderate
Cholesterol may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Riociguat which could result in a lower serum level and potentially a reduction in efficacy.
Fimasartan
Moderate
Cholesterol may increase the excretion rate of Fimasartan which could result in a lower serum level and potentially a reduction in efficacy.
Delafloxacin
Moderate
Cholesterol may increase the excretion rate of Delafloxacin which could result in a lower serum level and potentially a reduction in efficacy.
Brigatinib
Moderate
Cholesterol may increase the excretion rate of Brigatinib which could result in a lower serum level and potentially a reduction in efficacy.
Enasidenib
Moderate
Cholesterol may increase the excretion rate of Enasidenib which could result in a lower serum level and potentially a reduction in efficacy.
Testosterone cypionate
Moderate
Cholesterol may increase the excretion rate of Testosterone cypionate which could result in a lower serum level and potentially a reduction in efficacy.
Testosterone enanthate
Moderate
Cholesterol may increase the excretion rate of Testosterone enanthate which could result in a lower serum level and potentially a reduction in efficacy.
Pravastatin
Moderate
Cholesterol may increase the excretion rate of Pravastatin which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estrogens
Moderate
Cholesterol may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Gefitinib which could result in a lower serum level and potentially a reduction in efficacy.
Cerivastatin
Moderate
Cholesterol may increase the excretion rate of Cerivastatin which could result in a lower serum level and potentially a reduction in efficacy.
Teniposide
Moderate
Cholesterol may increase the excretion rate of Teniposide which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Prazosin which could result in a lower serum level and potentially a reduction in efficacy.
Raloxifene
Moderate
Cholesterol may increase the excretion rate of Raloxifene which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Celecoxib which could result in a lower serum level and potentially a reduction in efficacy.
Zidovudine
Moderate
Cholesterol may increase the excretion rate of Zidovudine which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Ritonavir which could result in a lower serum level and potentially a reduction in efficacy.
Vincristine
Moderate
Cholesterol may increase the excretion rate of Vincristine which could result in a lower serum level and potentially a reduction in efficacy.
Methotrexate
Moderate
Cholesterol may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.
Ivermectin
Moderate
Cholesterol may increase the excretion rate of Ivermectin which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Imatinib which could result in a lower serum level and potentially a reduction in efficacy.
Sumatriptan
Moderate
Cholesterol may increase the excretion rate of Sumatriptan which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Tamoxifen which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetil
Moderate
Cholesterol may increase the excretion rate of Mycophenolate mofetil which could result in a lower serum level and potentially a reduction in efficacy.
Daunorubicin
Moderate
Cholesterol may increase the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Nitrofurantoin
Moderate
Cholesterol may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.
Lamivudine
Moderate
Cholesterol may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.
Irinotecan
Moderate
Cholesterol may increase the excretion rate of Irinotecan which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Etoposide which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Donepezil which could result in a lower serum level and potentially a reduction in efficacy.
Dactinomycin
Moderate
Cholesterol may increase the excretion rate of Dactinomycin which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Ezetimibe which could result in a lower serum level and potentially a reduction in efficacy.
Doxorubicin
Moderate
Cholesterol may increase the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Tegaserod which could result in a lower serum level and potentially a reduction in efficacy.
Mitoxantrone
Moderate
Cholesterol may increase the excretion rate of Mitoxantrone which could result in a lower serum level and potentially a reduction in efficacy.
Cholesterol may increase the excretion rate of Dasatinib which could result in a lower serum level and potentially a reduction in efficacy.
Showing 50 of 100 interactions
Drug targets(5)
Proteins and enzymes this drug interacts with in the body
Choline-phosphate cytidylyltransferase B
PCYT1B
activator
Specific functioncholine-phosphate cytidylyltransferase activity
Cellular location
Cytoplasm
General function & pharmacology
Catalyzes the key rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis
Nuclear receptor subfamily 1 group I member 3
NR1I3
Specific functionDNA-binding transcription activator activity, RNA polymerase II-specific
Cellular location
Nucleus
General function & pharmacology
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital responsive element module of the human CYP2B6 gene and the CYP3A4 xenobiotic response element
Vitamin D3 receptor
VDR
Specific functionbile acid nuclear receptor activity
Cellular location
Nucleus
General function & pharmacology
Nuclear receptor for calcitriol, the active form of vitamin D3 which mediates the action of this vitamin on cells .
PMID:10678179 PMID:15728261 PMID:16913708 PMID:28698609 PMID:37478846
Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR .
PMID:28698609
The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes .
PMID:28698609
Plays a central role in calcium homeostasis (By similarity). Also functions as a receptor for the secondary bile acid lithocholic acid (LCA) and its metabolites PMID:12016314 PMID:32354638
PMID:10678179 PMID:15728261 PMID:16913708 PMID:28698609 PMID:37478846
Enters the nucleus upon vitamin D3 binding where it forms heterodimers with the retinoid X receptor/RXR .
PMID:28698609
The VDR-RXR heterodimers bind to specific response elements on DNA and activate the transcription of vitamin D3-responsive target genes .
PMID:28698609
Plays a central role in calcium homeostasis (By similarity). Also functions as a receptor for the secondary bile acid lithocholic acid (LCA) and its metabolites PMID:12016314 PMID:32354638
C-type lectin domain family 4 member E
CLEC4E
ligand
Specific functioncalcium ion binding
Cellular location
Cell membrane
General function & pharmacology
Calcium-dependent lectin that acts as a pattern recognition receptor (PRR) of the innate immune system: recognizes damage-associated molecular patterns (DAMPs) of abnormal self and pathogen-associated molecular patterns (PAMPs) of bacteria and fungi .
PMID:18509109 PMID:23602766
The PAMPs notably include mycobacterial trehalose 6,6'-dimycolate (TDM), a cell wall glycolipid with potent adjuvant immunomodulatory functions .
PMID:23602766 PMID:24101491
Interacts with signaling adapter Fc receptor gamma chain/FCER1G to form a functional complex in myeloid cells (By similarity). Binding of mycobacterial trehalose 6,6'-dimycolate (TDM) to this receptor complex leads to phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) of FCER1G, triggering activation of SYK, CARD9 and NF-kappa-B, consequently driving maturation of antigen-presenting cells and shaping antigen-specific priming of T-cells toward effector T-helper 1 and T-helper 17 cell subtypes (By similarity). Also recognizes alpha-mannose residues on pathogenic fungi of the genus Malassezia and mediates macrophage activation (By similarity).
Through recognition of DAMPs released upon nonhomeostatic cell death, enables immune sensing of damaged self and promotes inflammatory cell infiltration into the damaged tissue (By similarity)
PMID:18509109 PMID:23602766
The PAMPs notably include mycobacterial trehalose 6,6'-dimycolate (TDM), a cell wall glycolipid with potent adjuvant immunomodulatory functions .
PMID:23602766 PMID:24101491
Interacts with signaling adapter Fc receptor gamma chain/FCER1G to form a functional complex in myeloid cells (By similarity). Binding of mycobacterial trehalose 6,6'-dimycolate (TDM) to this receptor complex leads to phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) of FCER1G, triggering activation of SYK, CARD9 and NF-kappa-B, consequently driving maturation of antigen-presenting cells and shaping antigen-specific priming of T-cells toward effector T-helper 1 and T-helper 17 cell subtypes (By similarity). Also recognizes alpha-mannose residues on pathogenic fungi of the genus Malassezia and mediates macrophage activation (By similarity).
Through recognition of DAMPs released upon nonhomeostatic cell death, enables immune sensing of damaged self and promotes inflammatory cell infiltration into the damaged tissue (By similarity)
Nuclear receptor ROR-alpha
RORA
Specific functionbeta-catenin binding
Cellular location
Nucleus
General function & pharmacology
Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively.
Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development .
PMID:29656859
Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction.
Regulates the circadian expression of several clock genes, including CLOCK, BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock.
Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes.
In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC1 and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms.
May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus.
Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling
Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development .
PMID:29656859
Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction.
Regulates the circadian expression of several clock genes, including CLOCK, BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock.
Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes.
In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC1 and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms.
May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus.
Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling
Transporters(2)
Proteins that transport this drug across cell membranes
ATP-dependent translocase ABCB1
ABCB1
inhibitor
Specific functionABC-type xenobiotic transporter activity
Cellular location
Cell membrane
General function & pharmacology
Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
Broad substrate specificity ATP-binding cassette transporter ABCG2
ABCG2
inducer
Specific functionABC-type xenobiotic transporter activity
Cellular location
Cell membrane
General function & pharmacology
Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells .
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562
Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388
In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239
Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).
Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042
In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).
In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response
PMID:11306452 PMID:12958161 PMID:19506252 PMID:20705604 PMID:28554189 PMID:30405239 PMID:31003562
Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme .
PMID:20705604 PMID:23189181
Also mediates the efflux of sphingosine-1-P from cells .
PMID:20110355
Acts as a urate exporter functioning in both renal and extrarenal urate excretion .
PMID:19506252 PMID:20368174 PMID:22132962 PMID:31003562 PMID:36749388
In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates .
PMID:12682043 PMID:28554189 PMID:30405239
Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity).
Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux .
PMID:11306452 PMID:12477054 PMID:15670731 PMID:18056989 PMID:31254042
In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity).
In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response
Biological pathways(41)
metabolic
metabolic
metabolic
disease
disease
disease
disease
disease
disease
disease
disease
disease
Experimental properties(3)
Protein Data Bank entries(821)
1lri
1n83
1zhy
2rh1
2zxe
3a3y
3am6
3d4s
3gki
3jd8
3k2s
3kdp
3n9y
3ny8
3ny9
3nya
3pds
3wgu
3wgv
4boe
4bqu
4dkl
4eiy
4hqj
4hyt
4ib4
4m48
4nc3
4ntj
4or2
4pxz
4res
4ret
4xe5
4xnu
4xnv
4xnx
4xp1
4xp4
4xp5
4xp6
4xp9
4xpa
4xpb
4xpf
4xpg
4xph
4xpt
4xt1
5avq
5avr
5avs
5avt
5avu
5avv
5avw
5avx
5avy
5avz
5aw0
5aw1
5aw2
5aw3
5aw4
5aw5
5aw6
5aw7
5aw8
5aw9
5c1m
5d5a
5d5b
5d6l
5i6x
5i71
5i73
5i74
5i75
5iu4
5iu7
5iu8
5iua
5iub
5jqh
5jtb
5k2a
5k2b
5k2c
5k2d
5l7d
5lwe
5mzj
5mzp
5n2r
5nlx
5nm2
5nm4
5olg
5olh
5olo
5olv
5olz
5om1
5om4
5oqt
5sy1
5tcx
5tvn
5uph
5uvi
5vra
5wb2
5wvr
5x7d
5x93
5xr8
5xra
5zm5
5zm7
6a15
6a93
6a94
6aqf
6awn
6awo
6awp
6awq
6b73
6bhu
6co7
6d35
6drx
6dry
6drz
6ds0
6f34
6gt3
6gyh
6hij
6ibb
6idf
6iiu
6iiv
6iyc
6jmq
6jxh
6jxi
6jxj
6jxk
6jzh
6kuw
6l47
6l48
6lfm
6lfo
6lpj
6lpk
6lpl
6lqg
6lr4
6lw5
6m0f
6m0z
6m2r
6m38
6m3z
6m47
6mg8
6msm
6n4b
6n7g
6n7h
6n7k
6nbf
6nbh
6nbi
6nf4
6o1v
6o3c
6oba
6omm
6os1
6os2
6pb0
6pb1
6peq
6prz
6ps0
6ps1
6ps2
6ps3
6ps4
6ps5
6ps6
6ps7
6pt0
6pt2
6qee
6qex
6rvd
6rz6
6rz7
6rz9
6s0l
6s0q
6s7p
6t4g
6t4i
6t9n
6t9o
6tlq
6tpk
6ucb
6ud4
6ud8
6uy0
6v22
6v35
6v38
6v3f
6v9s
6vi4
6vn7
6vum
6vxh
6vxi
6vxj
6w5r
6w5s
6w5t
6w5u
6w5v
6wbf
6wbg
6wbm
6wbn
6wgt
6wh4
6wiv
6wlw
6wm2
6wqa
6xbj
6xbk
6xbl
6zdr
6zdv
7a65
7a69
7a6c
7a6e
7a6f
7aro
7bts
7bu6
7bu7
7bvq
7c9i
7ca3
7cfm
7cfn
7ckw
7ckx
7cky
7ckz
7cu3
7cum
7cz5
7d76
7d77
7d8x
7d91
7d92
7d93
7d94
7ddf
7ddh
7ddi
7ddk
7ddl
7df8
7dfw
7dfz
7drt
7dty
7duq
7dur
7dw9
7e14
7e2x
7e2y
7e2z
7e32
7ehl
7ejx
7eki
7ekp
7ekt
7et1
7euo
7evm
7f16
7f61
7f6g
7f6h
7f6i
7f6v
7f9y
7fd2
7fdv
7fee
7fin
7fiy
7fjd
7fje
7jv5
7jvp
7jvq
7ky5
7ky7
7ky8
7kya
7lft
7lgu
7lgw
7lh2
7li7
7lia
7ljc
7ljd
7lkp
7m5x
7m5y
7m95
7mfi
7mgw
7mix
7miy
7n4u
7n4v
7n4x
7n6q
7n6r
7na7
7na8
7neq
7nf6
7nf8
7niu
7niv
7niw
7oca
7oce
7oj8
7ojh
7oji
7p00
7p02
7pp1
7px4
7pxe
7pxg
7pxh
7pyr
7q1u
7q6z
7qtv
7r8a
7r8b
7r8d
7r8e
7rhq
7rhr
7rkm
7rm5
7roq
7rr9
7she
7shf
7sil
7sim
7sk3
7sk4
7sk5
7sk7
7sk8
7sk9
7sl8
7smm
7smq
7smr
7sms
7smt
7sv7
7svd
7t2g
7t92
7tai
7tbw
7tby
7tbz
7tc0
7tj8
7tj9
7tvz
7ty4
7ty6
7ty7
7ty8
7tya
7uhg
7ura
7urc
7urd
7usw
7usx
7uz3
7uze
7uzq
7v07
7v0k
7v0s
7v19
7v3z
7v62
7v6y
7v6z
7v73
7v74
7v75
7vab
7vdh
7vdl
7vdm
7vfx
7vgy
7vgz
7vl8
7vl9
7vla
7vod
7voe
7vr7
7vr8
7vuy
7vuz
7vv0
7vv3
7vv4
7vv5
7vv6
7w2z
7w9w
7wc4
7wc5
7wc6
7wc7
7wc8
7wc9
7we4
7wel
7wfr
7wfw
7wgd
7wgt
7wld
7wlw
7wq3
7wq4
7wu4
7wu5
7wwb
7wys
7wyt
7wyu
7wyv
7wyw
7wyx
7wyy
7wyz
7wz0
7x21
7x22
7x24
7x2c
7x2d
7x2f
7xbw
7xbx
7xem
7xer
7xeu
7xt8
7xt9
7xtc
7xve
7xvf
7xw5
7xw6
7xzh
7y27
7y45
7y46
7y48
7y5t
7y5x
7y5z
7yae
7yfc
7yfd
7ykd
7zi0
7zxn
7zyi
8a2o
8a2p
8bht
8bi0
8bjf
8c9w
8cic
8crq
8crr
8crt
8cs9
8csx
8ct2
8ct3
8cte
8cu6
8cu7
8cub
8cxo
8dpf
8dpg
8dph
8dpi
8du3
8e0g
8ef5
8ef6
8efl
8efo
8eig
8eio
8eiq
8eog
8epl
8esk
8f1d
8f2s
8f6y
8f6z
8f7q
8f7r
8f7s
8f7w
8fd7
8fhd
8fhs
8fyn
8g05
8ghf
8gi8
8gi9
8gn7
8gne
8gnk
8h0q
8h8j
8ha0
8haf
8hdo
8hdp
8hk2
8hnk
8hnl
8hnm
8hnn
8hsi
8i2g
8ijl
8ijm
8ijv
8ijw
8ijx
8im7
8irr
8iru
8irv
8ivl
8iz4
8izb
8j6m
8j6p
8j6q
8j7f
8j7m
8jbk
8jbl
8jbm
8jc0
8jcw
8jcy
8jd0
8jd1
8jd3
8jd5
8jew
8jez
8jf1
8jfz
8jhy
8jii
8jil
8jim
8jjp
8jkv
8jl1
8jl3
8jl4
8jmn
8jqr
8jt6
8jt8
8jwy
8jwz
8jxq
8jzs
8jzx
8k2w
8k2x
8k66
8k69
8k8e
8k9r
8k9t
8kco
8kcp
8kcs
8kct
8kcu
8kcw
8kh4
8kh5
8ozh
8ozj
8ozp
8ozq
8pg0
8pjk
8pkm
8pm6
8pmj
8pwn
8pxo
8py4
8q7b
8qcm
8qjf
8qk6
8qki
8rln
8rqq
8s3e
8sg1
8sgw
8sh3
8shc
8si2
8si3
8si4
8si5
8si6
8si7
8si8
8sia
8sie
8sjx
8sjy
8smv
8sr7
8sr8
8sr9
8sra
8srb
8src
8srd
8sre
8srf
8srg
8srh
8sri
8srj
8srk
8ss2
8ss3
8ss6
8ss7
8ss8
8ss9
8sza
8szb
8szg
8szh
8szi
8t03
8t04
8t05
8t2v
8t3s
8t3v
8t56
8t57
8t6u
8t6v
8tkp
8tw4
8tw6
8u2z
8u4n
8u4o
8u4p
8u4q
8u4r
8u4s
8u4t
8ubr
8ugy
8uh3
8uuk
8v0g
8v12
8v1g
8v7z
8v81
8vy7
8vy9
8w2l
8w4a
8w6h
8w6o
8w88
8w8b
8wa5
8we6
8we7
8we8
8we9
8wjx
8woq
8wor
8wos
8wot
8wpu
8wrb
8wxe
8wy0
8x52
8x53
8x54
8x5b
8x5f
8x90
8x91
8x93
8x94
8xbs
8xc1
8xgm
8xmm
8xor
8xos
8xql
8xqn
8xqo
8xqp
8xqs
8xqt
8y6i
8yc0
8yky
8yn2
8yn3
8yn4
8yn5
8yn6
8yn7
8yn8
8yn9
8yna
8yr2
8yut
8yuu
8yuv
8yvu
8zle
8zsj
9axf
9b36
9b37
9b8o
9bbc
9brd
9bvh
9c3e
9cia
9cui
9cuk
9d3e
9d3g
9deq
9dw9
9eo4
9euo
9eup
9f41
9gyo
9ij9
9ija
9ima
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cholesterol
Additional database identifiers
Drugs Product Database (DPD)
9250
ChemSpider
5775
BindingDB
20192
PDB
CLR
ZINC
ZINC000003875383
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8755
GenAtlas
PCYT1B
GeneCards
PCYT1B
GenBank Gene Database
AF052510
GenBank Protein Database
3153239
UniProt Accession
PCY1B_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7969
GeneCards
NR1I3
GenBank Gene Database
Z30425
GenBank Protein Database
458542
Guide to Pharmacology
607
UniProt Accession
NR1I3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12679
GenAtlas
VDR
GeneCards
VDR
GenBank Gene Database
J03258
GenBank Protein Database
340203
Guide to Pharmacology
605
UniProt Accession
VDR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:14555
GeneCards
CLEC4E
Guide to Pharmacology
2929
UniProt Accession
CLC4E_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10258
GeneCards
RORA
Guide to Pharmacology
598
UniProt Accession
RORA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:74
GenAtlas
ABCG2
GeneCards
ABCG2
GenBank Gene Database
AF103796
GenBank Protein Database
4185796
Guide to Pharmacology
792
UniProt Accession
ABCG2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
Show earlier publications
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 30 days ago(4 Mar 2026)